Lexeo Therapeutics, Inc. Common Stock

NasdaqGM LXEO

Lexeo Therapeutics, Inc. Common Stock Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Lexeo Therapeutics, Inc. Common Stock Gross Profit Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
NasdaqGM: LXEO

Lexeo Therapeutics, Inc. Common Stock

CEO Mr. R. Nolan Townsend
IPO Date Nov. 3, 2023
Location United States
Headquarters 345 Park Avenue South
Employees 69
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

StockViz Staff

January 15, 2025

Any question? Send us an email